Molecular Pathogenesis of Ovarian Cancer and Therapeutic Strategies
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 20 May 2026 | Viewed by 4
Special Issue Editor
Special Issue Information
Dear Colleagues,
Epithelial ovarian cancer is the deadliest gynecological cancer in the U.S. and developed countries, often diagnosed late and developing drug resistance. It includes subtypes such as high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous, with high-grade serous being the most lethal and the most difficult to treat. These cancers exhibit significant genetic diversity, particularly in high-grade serous (HGSC) tumors. Approximately 95% of HGSC cases harbor TP53 mutations, leading to S-phase checkpoint deficiency and a reliance on the G2/M checkpoint. In total, 40% also have mutations in tumor suppressor genes like BRCA1/2, affecting HR DNA repair, making them vulnerable to PARP inhibitors. However, resistance develops quickly, necessitating the identification of new molecular targets to extend survival.
Recent studies have identified molecular targets related to spindle assembly, PI3K pathways, cell cycle, DNA repair, and immune modulation. This review explores these findings, resultant therapeutic strategies, and/or their potential to develop new therapies, especially for hard-to-treat subtypes like high-grade serous ovarian cancer.
Dr. Jayakumar R. Nair
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- pathogenic mutations
- target therapy
- genetic heterogeneity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
